Modern Neoadjuvant Chemotherapy for Breast-Conserving Surgery

Overview

 

Featured Webinar

Featured Article

Petruolo O, Sevilimedu V, Montagna G, Le T, Morrow M, Barrio AV. How Often Does Modern Neoadjuvant Chemotherapy Downstage Patients to Breast-Conserving Surgery?.
Ann Surg Oncol. 2021;28(1):287-294. doi:10.1245/s10434-020-08593-5

 

Expert Reviews

Methodological Reviewer
Alison Laws MD, FACS, Brigham and Women's Hospital/Dana-Farber Cancer Institute
Clinical Reviewer
Erin Cordeiro MD, MSc FRCSC, University of Ottawa
Clinical Reviewer
Pamela Hebbard MD, FRCSC, University of Manitoba

 

Questions

Please read the above articles and be prepared to discuss the following:

  1. What is the clinical question being addressed? 
  2. Was the assignment of patients to treatment randomized? 
  3. Were all patients who entered the trial properly accounted for and attributed at its conclusions? 
  4. Were patients, their clinicians and study personnel “blind” to treatment? 
  5. Were the groups similar at the start of the trial? 
  6. Aside from the experimental intervention, were the groups treated equally? 
  7. How large and precise was the treatment effect? 
  8. Can the results be applied to my patient care? 
  9. Were all clinically important outcomes considered? 
  10. Are the likely treatment benefits worth the potential harm and costs? 
  11. State the conclusion. Have the authors addressed the question posed? 
  12. Does the evidence support the conclusion?